Deletion of endothelial IGFBP5 protects against ischaemic hindlimb injury by promoting angiogenesis

Abstract

Background: Angiogenesis is critical for forming new blood vessels from antedating vascular vessels. The endothelium is essential for angiogenesis, vascular remodelling and minimisation of functional deficits following ischaemia. The insulin-like growth factor (IGF) family is crucial for angiogenesis. Insulin-like growth factor-binding protein 5 (IGFBP5), a binding protein of the IGF family, may have places in angiogenesis, but the mechanisms are not yet completely understood. We sought to probe whether IGFBP5 is involved in pathological angiogenesis and uncover the molecular mechanisms behind it.

Methods and results: IGFBP5 expression was elevated in the vascular endothelium of gastrocnemius muscle from critical limb ischaemia patients and hindlimb ischaemic (HLI) mice and hypoxic human umbilical vein endothelial cells (HUVECs). In vivo, loss of endothelial IGFBP5 (IGFBP5^EKO) facilitated the recovery of blood vessel function and limb necrosis in HLI mice. Moreover, skin damage healing and aortic ring sprouting were faster in IGFBP5^EKO mice than in control mice. In vitro, the genetic inhibition of IGFBP5 in HUVECs significantly promoted tube formation, cell proliferation and migration by mediating the phosphorylation of IGF1R, Erk1/2 and Akt. Intriguingly, pharmacological treatment of HUVECs with recombinant human IGFBP5 ensued a contrasting effect on angiogenesis by inhibiting the IGF1 or IGF2 function. Genetic inhibition of IGFBP5 promoted cellular oxygen consumption and extracellular acidification rates via IGF1R-mediated glycolytic adenosine triphosphate (ATP) metabolism. Mechanistically, IGFBP5 exerted its role via E3 ubiquitin ligase Von Hippel-Lindau (VHL)-regulated HIF1α stability. Furthermore, the knockdown of the endothelial IGF1R partially abolished the reformative effect of IGFBP5^EKO mice post-HLI.

Conclusion: Our findings demonstrate that IGFBP5 ablation enhances angiogenesis by promoting ATP metabolism and stabilising HIF1α, implying IGFBP5 is a novel therapeutic target for treating abnormal angiogenesis-related conditions.

Keywords

angiogenesis / cell proliferation / IGF1/IGF2 / IGF1R / IGFBP5

References

[1] BackM, Yurdagul A, TabasI, OorniK, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389-406.

[2] WangX, SuB, GaoB, et al. Cascaded bio-responsive delivery of eNOS gene and ZNF580 gene to collaboratively treat hindlimb ischemia via pro-angiogenesis and anti-inflammation. Biomater Sci. 2020;8(23):6545-6560.

[3] RawanduzyCA, EarlE, MayerG, Lucke-Wold B. Pediatric stroke: a review of common etiologies and management strategies. Biomedicines. 2022;11(1):2.

[4] TabarestaniA, PatelA, ReddyA, Sharaf R, Lucke-WoldB. Vasospasm management strategies. Int J Med Pharm Res. 2023;4(2):150-160.

[5] KinlayS. Management of critical limb ischemia. Circ Cardiovasc Interv. 2016;9(2):e001946.

[6] UccioliL, MeloniM, IzzoV, Giurato L, MerollaS, GandiniR. Critical limb ischemia: current challenges and future prospects. Vasc Health Risk Manag. 2018;14:63-74.

[7] PandeRL, Perlstein TS, BeckmanJA, CreagerMA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124(1):17-23.

[8] ForemanM, MaddyK, PatelA, Reddy A, CostelloM, Lucke-WoldB. Differentiating lumbar spinal etiology from peripheral plexopathies. Biomedicines. 2023;11(3):756.

[9] RainoneGJ, Zelmanovich R, LaurentD, Lucke-WoldB. How war has shaped neurosurgery. World Neurosurg. 2023;178:136-144.

[10] KioutchoukovaIP, FosterDT, ThakkarRN, et al. Neurologic orphan diseases: emerging innovations and role for genetic treatments. World J Exp Med. 2023;13(4):59-74.

[11] LairdJR, SinghGD, ArmstrongEJ. Contemporary management of critical limb ischemia: the BEST is yet to come. J Am Coll Cardiol. 2016;67(16):1914-1916.

[12] WangX, ZhangJ, CuiW, et al. Composite hydrogel modified by IGF-1C domain improves stem cell therapy for limb ischemia. ACS Appl Mater Interfaces. 2018;10(5):4481-4493.

[13] CarmelietP. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932-936.

[14] CarmelietP, JainRK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.

[15] PughCW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9(6):677-684.

[16] SimonsM. Angiogenesis: where do we stand now? Circulation. 2005;111(12):1556-1566.

[17] SongC, WangS, FuZ, et al. IGFBP5 promotes diabetic kidney disease progression by enhancing PFKFB3-mediated endothelial glycolysis. Cell Death Dis. 2022;13(4):340.

[18] AllardJB, DuanC. IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol (Lausanne). 2018;9:117.

[19] XuS, XuY, YinM, et al. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Theranostics. 2018;8(11):3007-3021.

[20] ZhaoK, LiX, ZhangM, et al. microRNA-181a promotes mitochondrial dysfunction and inflammatory reaction in a rat model of intensive care unit-acquired weakness by inhibiting IGFBP5 expression. J Neuropathol Exp Neurol. 2022;81(7):553-564.

[21] NguyenXX, Muhammad L, NietertPJ, Feghali-BostwickC. IGFBP-5 promotes fibrosis via increasing its own expression and that of other pro-fibrotic mediators. Front Endocrinol (Lausanne). 2018;9:601.

[22] SongSE, KimYW, KimJY, Lee DH, KimJR, ParkSY. IGFBP5 mediates high glucose-induced cardiac fibroblast activation. J Mol Endocrinol. 2013;50(3):291-303.

[23] SureshbabuA, Okajima H, YamanakaD, et al. IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells. J Cell Sci. 2012;125(pt 7):1693-1705.

[24] JiaY, LiT, HuangX, et al. Dysregulated DNA methyltransferase 3A upregulates IGFBP5 to suppress trophoblast cell migration and invasion in preeclampsia. Hypertension. 2017;69(2):356-366.

[25] HanN, ZhangF, LiG, et al. Local application of IGFBP5 protein enhanced periodontal tissue regeneration via increasing the migration, cell proliferation and osteo/dentinogenic differentiation of mesenchymal stem cells in an inflammatory niche. Stem Cell Res Ther. 2017;8(1):210.

[26] SimonS, Grabellus F, FerreraL, et al. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res. 2013;73(12):3661-3670.

[27] LiuL, WangJ, LiX, et al. MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma. Biochem Biophys Res Commun. 2015;457(4):621-626.

[28] LiJ, SongF, ChenR, et al. Bradykinin-pretreated human cardiac-specific c-kit(+) cells enhance exosomal miR-3059-5p and promote angiogenesis against hindlimb ischemia in mice. Stem Cell Rev Rep. 2023;19(7):2481-2496.

[29] BaudinB, Bruneel A, BosselutN, VaubourdolleM. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc. 2007;2(3):481-485.

[30] LiJZ, ZhouXX, WuWY, et al. Concanavalin A promotes angiogenesis and proliferation in endothelial cells through the Akt/ERK/cyclin D1 axis. Pharm Biol. 2022;60(1):65-74.

[31] BurriPH, DjonovV. Intussusceptive angiogenesis—the alternative to capillary sprouting. Mol Aspects Med. 2002;23(6S):S1-S27.

[32] AckermannM, HoudekJP, GibneyBC, et al. Sprouting and intussusceptive angiogenesis in postpneumonectomy lung growth: mechanisms of alveolar neovascularization. Angiogenesis. 2014;17(3):541-551.

[33] WestenskowPD, Kurihara T, AguilarE, et al. Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting. J Clin Invest. 2013;123(11):4900-4908.

[34] OladipupoS, HuS, KovalskiJ, et al. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc Natl Acad Sci U S A. 2011;108(32):13264-13269.

[35] SalihDA, Tripathi G, HoldingC, et al. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci U S A. 2004;101(12):4314-4319.

[36] LiG, CheH, WuWY, et al. Bradykinin-mediated Ca(2+) signalling regulates cell growth and mobility in human cardiac c-Kit(+) progenitor cells. J Cell Mol Med. 2018;22(10):4688-4699.

[37] SunN, WangJ, DouX, et al. A chiral microenvironment promotes retinal progenitor cell proliferation by activating the Akt and ERK pathways. Biomater Sci. 2022;10(20):5938-5946.

[38] SimonCM, Rauskolb S, GunnersenJM, et al. Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy. Acta Neuropathol. 2015;130(3):373-387.

[39] ZhongC, LiP, ArgadeS, et al. Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways. Nat Commun. 2020;11(1):6330.

[40] LinH, Muramatsu R, MaederaN, et al. Extracellular lactate dehydrogenase A release from damaged neurons drives central nervous system angiogenesis. EBioMedicine. 2018;27:71-85.

[41] Parra-BonillaG, Alvarez DF, AlexeyevM, VasauskasA, Stevens T. Lactate dehydrogenase a expression is necessary to sustain rapid angiogenesis of pulmonary microvascular endothelium. PLoS One. 2013;8(9):e75984.

[42] ColganSM, Mukherjee S, MajorP. Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis. Clin Colorectal Cancer. 2007;6(6):442-446.

[43] KoukourakisMI, Giatromanolaki A, SivridisE, GatterKC, HarrisAL. Tumour angiogenesis research G. lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway—a report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006;24(26):4301-4308.

[44] RenR, GuoJ, ShiJ, TianY, LiM, KangH. PKM2 regulates angiogenesis of VR-EPCs through modulating glycolysis, mitochondrial fission, and fusion. J Cell Physiol. 2020;235(9):6204-6217.

[45] AjdukovicJ. HIF-1—a big chapter in the cancer tale. Exp Oncol. 2016;38(1):9-12.

[46] MaxwellPH, Wiesener MS, ChangGW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-275.

[47] BhallaS, MehanS, KhanA, Rehman MU. Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neurosci Biobehav Rev. 2022;142:104896.

[48] FangF, Goldstein JL, ShiX, LiangG, BrownMS. Unexpected role for IGF-1 in starvation: maintenance of blood glucose. Proc Natl Acad Sci U S A. 2022;119(32):e2208855119.

[49] MatsushitaM, FujitaK, HatanoK, De Velasco MA, UemuraH, NonomuraN. Connecting the dots between the gut-IGF-1-prostate axis: a role of IGF-1 in prostate carcinogenesis. Front Endocrinol (Lausanne). 2022;13:852382.

[50] WanY, GaoW, ZhouK, et al. Role of IGF-1 in neuroinflammation and cognition deficits induced by sleep deprivation. Neurosci Lett. 2022;776:136575.

[51] DingM, BruickRK, YuY. Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling. Nat Cell Biol. 2016;18(3):319-327.

[52] SachdevD, YeeD. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6(1):1-12.

[53] LiX, NoellG, TabibT, et al. Single cell RNA sequencing identifies IGFBP5 and QKI as ciliated epithelial cell genes associated with severe COPD. Respir Res. 2021;22(1):100.

[54] LaiG, WangL, LiZ, ZhaoY. Homocysteine downregulates cardiac homeobox transcription factor NKX2.5 via IGFBP5. Am J Physiol Heart Circ Physiol. 2020;319(6):H1380-H1386.

[55] KarabulutS, KayaZ, AmuranGG, et al. Correlation between the DNA methylation and gene expression of IGFBP5 in breast cancer. Breast Dis. 2016;36(4):123-131.

[56] GarnerCP, DingYC, JohnEM, et al. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 2008;123(3):247-255.

[57] BuchmanAS, YuL, PetyukVA, et al. Cognition may link cortical IGFBP5 levels with motor function in older adults. PLoS One. 2019;14(8):e0220968.

[58] DongC, ZhangJ, FangS, Liu F. IGFBP5 increases cell invasion and inhibits cell proliferation by EMT and Akt signaling pathway in glioblastoma multiforme cells. Cell Div. 2020;15:4.

[59] AkkiprikM, HuL, SahinA, Hao X, ZhangW. The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer. BMC Cancer. 2009;9:103.

[60] WangT, WangCJ, TianS, Song HB. Overexpressed IGFBP5 promotes cell proliferation and inhibits apoptosis of nucleus pulposus derived from rats with disc degeneration through inactivating the ERK/MAPK axis. J Cell Biochem. 2019;120(11):18782-18792.

[61] LiJ, DiaoS, YangH, Cao Y, DuJ, YangD. IGFBP5 promotes angiogenic and neurogenic differentiation potential of dental pulp stem cells. Dev Growth Differ. 2019;61(9):457-465.

[62] WangY, JiaZ, DiaoS, et al. IGFBP5 enhances osteogenic differentiation potential of periodontal ligament stem cells and Wharton's jelly umbilical cord stem cells, via the JNK and MEK/Erk signalling pathways. Cell Prolif. 2016;49(5):618-627.

[63] PollakM. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-169.

[64] HwaV, OhY, RosenfeldRG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20(6):761-787.

[65] MiyakeH, PollakM, GleaveME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. 2000;60(11):3058-3064.

[66] BobolaN, EngistB. IGFBP5 is a potential regulator of craniofacial skeletogenesis. Genesis. 2008;46(1):52-59.

[67] NeuzilletY, Chapeaublanc E, KruckerC, et al. IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer. BMC Cancer. 2017;17(1):636.

[68] AhluwaliaA, Tarnawski AS. Critical role of hypoxia sensor–HIF-1alpha in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem. 2012;19(1):90-97.

[69] FoxlerDE, BridgeKS, JamesV, et al. The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat Cell Biol. 2012;14(2):201-208.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.